Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lower Manufacturing Costs Integral To Perrigo 2003 Strategy, CEO Says

This article was originally published in The Tan Sheet

Executive Summary

One of Perrigo's primary goals for the coming fiscal year will be to reduce its manufacturing expenditures and improve its "low-cost supplier position.

You may also be interested in...



Perrigo Boosts R&D Spending, Focuses On Quality Control

Perrigo plans to increase R&D spending in the second half of FY 2001 pending a favorable FDA follow-up manufacturing audit of the firm's Allegan, Mich. facility, President & CEO David Gibbons told analysts during a conference call Jan. 23.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS094362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel